Consensus on barriers and strategies for optimal clinical practice use of GLP-1 RAs in patients with type 2 diabetes and high cardiovascular risk or established cardiovascular disease.
This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.